Supplementary Table S1. Factors associated with HBV DNA suppression after 48 weeks of treatment stratified by baseline HBV DNA.

	Crude RR (95% CI)	P	Adjusted RR (95% CI)*	P	Adjusted RR (95% CI)#	P
Baseline HBV DNA <20,000 IU/ml						
cART						
3TC-based	Reference		Reference		Reference	
TDF+3TC-based	1.01 (0.94-1.09)	0.74	1.01 (0.93-1.10)	0.84	1.01 (0.93-1.10)	0.78
CD4 cell count						
≤200 cells/μl	Reference		Reference		Reference	
>200 cells/μl	1.06 (0.98-1.14)	0.16	1.04 (0.98-1.10)	0.21	1.04 (0.98-1.11)	0.18
Baseline HIV RNA (per 1 log copy/ml increase)	0.97 (0.91-1.03)	0.28				
Baseline HBeAg						
Negative	Reference		Reference			
Positive	1.03 (0.99-1.06)	0.16	1.23 (0.93-1.63)	0.15		
Baseline qHBsAg (per 1 logIU/ml increase)	0.98 (0.94-1.01)	0.21			0.98 (0.95-1.02)	0.30
CD4 count at week 48 (cells/μL)						
<350	Reference					
>350	1.06 (0.98-1.14)	0.16				
Baseline HBV DNA ≥20,000 IU/ml						
cART						
3TC-based	Reference		Reference		Reference	
TDF+3TC-based	2.10 (1.22-3.61)	0.007	1.96 (1.21- 3.17)	0.006	1.88 (1.21-2.91)	0.005
CD4 cell count						
≤200 cells/μl	Reference		Reference		Reference	
>200 cells/μl	0.90 (0.59-1.39)	0.65	0.82 (0.58-1.17)	0.27	0.75 (0.52-1.07)	0.11
Baseline HIV RNA (per 1 log copy/ml) increase	1.12 (0.85-1.48)	0.43				
Baseline HBeAg						
Negative	Reference		Reference			
Positive	0.36 (0.22-0.59)	<0.001	0.38 (0.23-0.63)	<0.001		
Baseline qHBsAg (per 1 logIU/ml increase)	0.51 (0.39-0.67)	<0.001			0.49 (0.37-0.66)	<0.001
CD4 count at week 48 (cells/μL)						
<350	Reference					
>350	1.10 (0.72-1.66)	0.66				

RR, relative risk; cART, combination antiretroviral therapy; 3TC, lamivudine; TDF, tenofovir; HBeAg, HBV e antigen; qHBsAg, HBV surface antigen quantification.

a, Since baseline CD4 cell count were not balanced in two treatment groups, we also adjusted for baseline CD4 cell count in multivariate models.

b. Sex, age and routes of transmission were also adjusted for in multivariate analyses. Of note, they were not significantly associated with HBV DNA suppression in univariate analysis.

*, adjusted for baseline HBeAg in addition to sex, age and routes of transmission.

#, adjusted for baseline qHBsAg in addition to sex, age and routes of transmission.

Supplementary Table S2. Factors associated with HBV DNA suppression after 48 weeks of treatment stratified by baseline HBV e antigen.

Baseline HBeAg negative					
	HBV DNA Suppression rate at week 48 [n/N (%)]	Crude RR (95%CI)	P	Adjusted RR(95%CI)	P
cART					
3TC-based	38/42 (90.5)	Reference		Reference	
TDF+3TC-based	68/70 (97.1)	1.07 (0.97-1.19)	0.19	1.08 (0.97-1.21)	0.16
CD4 cell count					
≤200 cells/μl	51/54 (94.4)	Reference		Reference	
>200 cells/μl	55/58 (94.8)	1.00 (0.92-1.10)	0.93	0.95 (0.86-1.05)	0.32
Baseline HIV RNA (per 1 log copy/ml increase)	Not applicable	0.98 (0.93-1.04)	0.51		
Baseline HBV DNA (per 1 logIU/ml increase)	Not applicable	0.97 (0.93-1.00)	0.075	0.97 (0.94-1.00)	0.059
CD4 count at week 48 (cells/μL)					
≤350	51/54 (94.4)	Reference			
>350	55/58 (94.8)	1.00 (0.92-1.10)	0.93		
Baseline HBeAg positive					
	HBV DNA Suppression rate at week 48 [n/N (%)]	Crude RR (95%CI)	P	Adjusted RR(95%CI)	P
cART					
3TC-based	2/18 (11.1)	Reference		Reference	
TDF+3TC-based	11/21 (52.4)	4.71 (1.18-18.86)	0.028	10.07 (2.30-44.22)	0.002
CD4 cell count					
≤200 cells/μl	7/22 (31.8)	Reference		Reference	
>200 cells/μl	6/17 (35.3)	1.11 (0.45-2.73)	0.82	0.29 (0.06-1.46)	0.13
Baseline HIV RNA (per 1 log copy/ml) increase	Not applicable	1.13 (0.69-1.84)	0.64		
Baseline HBV DNA (per 1 log IU/ml increase)	Not applicable	0.80 (0.70-0.90)	<0.001	0.94 (0.83-1.06)	0.31
CD4 count at week 48 (cells/μL)					
≤350	4/20 (20.0)	Reference			
>350	9/19 (47.4)	2.37 (0.86-6.50)	0.094		

HBeAg, hepatitis B e antigen; RR, relative risk; cART, combination antiretroviral therapy; 3TC, lamivudine; TDF, tenofovir.

a, Since baseline CD4 cell count were not balanced in two treatment groups, we also adjusted for baseline CD4 cell count in multivariate models.

b. Sex, age and routes of transmission were also adjusted for in multivariate analyses. cART regimens (3TC-based or TDF+3TC-based), baseline HBV DNA and baseline CD4 cell count were forced into the multivariate models; other factors with P values<0.15 in univariate models were also included in the multivariate models. Since CD4 cell count at week 48 was collinear with CD4 cell count at baseline, we did not include CD4 cell count at week 48 in the multivariate regression.

Supplementary Figure S1. HBV DNA suppression prior to, after 24 and 48 weeks of treatment. (A) Baseline HBV e antigen positive group;

(B) baseline HBV e antigen negative group. P values were calculated using Chi square test or Fisher exact test.